This list is limited to anti-cancer medicines that are centrally authorised in the European Union for children with a cancer (or a progressive neoplastic disease), see EMA. At this time, no comment is provided here on the degree of innovation, on the clinical utility, on treatment guidelines or on how often the medicines are used to treat children with cancer.
For cancer and other medicines that may be authorised for children, see our automatically updated webapp here. For FDA-approved medicines for the treatment of paediatric cancers, see this FDA page (98 medicines as of 2025-10-12). For trials in children of cancer medicines authorised in adults, see the analysis in our post (data as of 2022-04-24).
Table last updated: 2025-10-18 (36 rows). Not included: nationally authorised and supportive medicines (such as Pedmarqsi, authorised on 2023-05-26, indication: prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to less than 18 years of age with a localised, non-metastatic, solid tumour).